Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Gene editing could one day replace daily cholesterol or heart disease meds with a single treatment — but scientists say the permanence cuts both ways. A new perspective in JAMA Internal Medicine warns that irreversible genetic changes demand far higher safety standards, especially when millions of people could eventually receive these therapies. The cost hurdle — some treatments already top $1 million — adds another layer of complexity.
Gene editing is inching closer to a world where one treatment could keep your cholesterol in check or protect your heart for decades — no daily pills required. But University of Michigan cardiologists Eric D. Smith and Venkatesh L. Murthy are urging caution. In a new perspective published in JAMA Internal Medicine, they argue that the same permanence that makes gene therapy so appealing also makes it uniquely risky, especially when applied to common conditions like high cholesterol, obesity, and diabetes that already have adjustable, reversible treatments.
Unlike rare, life-threatening diseases where the risk-benefit math is clearer, widespread gene therapy means even rare side effects could still harm enormous numbers of people. And unlike a pill you can stop taking, a genetic change is hard — sometimes impossible — to undo.
Key Takeaways:
Why it matters: As gene editing moves from rare disorders to everyday diseases, the stakes get exponentially higher. Getting the safety, monitoring, and affordability frameworks right now could determine whether this technology becomes a medical breakthrough — or a cautionary tale.
